The Field Administration of Stroke Therapy – Magnesium Phase 3 Clinical Trial is an NIH-NINDS-sponsored study whose goal is to evaluate the effectiveness and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke.
    Stroke is the third leading cause of death and the leading cause of adult disability in the United States. Each year, 750,000 Americans suffer a symptomatic stroke. The purpose of this multi-center, randomized, double-blind, phase 3 trial is to demonstrate that paramedic initiation of the neuroprotective agent magnesium sulfate in the field is an effective and safe treatment for acute stroke. This study will analyze magnesium sulfate, an experimental therapy for stroke, versus placebo, among 1298 ambulance-transported patients with acute stroke. Study agent will be initiated within 2 hours of symptom onset in all patients, and within 1 hour of symptom onset in half the patients. This trial will also demonstrate that paramedics can safely, effectively, and rapidly start neuroprotective therapies for stroke.

Participating sites are up to all (~80) receiving hospitals and up to all Emergency Medical Systems in the County of Los Angeles.